Clinical Global Trials

{
  "development_finance_context": "GAVI, Global Fund, UNITAID, PMI, USAID funding dominant. Wellcome Trust largest private funder.",
  "global_registries_coverage": {
    "anzctr_australia": "5 trials — malaria research centers in Melbourne (Burnet Institute)",
    "chictr_china": "Limited malaria — primarily domestic infectious disease",
    "clinical_trials_eu": "12 EU-registered trials",
    "ctri_india": "18 trials — India significant manufacturer (Serum Institute)"
  },
  "global_trial_distribution": {
    "clinicaltrials_gov_count": 312,
    "estimated_non_us_registries": "200+ additional trials in WHO ICTRP member registries",
    "geographic_concentration": "Sub-Saharan Africa dominates — 68% of all active malaria trials",
    "most_active_countries": [
      "Kenya (45 trials)",
      "Uganda (38)",
      "Burkina Faso (31)",
      "Mali (28)",
      "Tanzania (24)",
      "United States (22)",
      "Thailand (19)"
    ]
  },
  "opportunity_assessment": "R21 scale-up is the near-term priority. Resistance crisis in SE Asia creates urgent Phase 3 need for alternative regimens.",
  "phase3_highlights": [
    {
      "countries": [
        "Burkina Faso",
        "Kenya",
        "Mali",
        "Tanzania"
      ],
      "drug": "R21/Matrix-M",
      "notes": "WHO prequalification received 2023. First malaria vaccine with >75% efficacy in high-transmission settings.",
      "sponsor": "Serum Institute / Oxford"
    }
  ],
  "query_summary": {
    "condition": "Malaria",
    "region": "global"
  },
  "regulatory_landscape": {
    "ema": "Article 58 mechanism for non-EU disease burden assessments. R21 assessed via UK MHRA.",
    "fda": "Limited footprint — malaria not a US priority market; few NDA filings",
    "nmpa_china": "Artemisinin derivatives approved; combination therapies standardized under WHO guidelines",
    "who_prequalification": "Primary pathway for SSA deployment. RTS,S and R21 both WHO-prequalified."
  },
  "unmet_needs_by_region": {
    "latin_america": "Vivax malaria (neglected vs. falciparum)",
    "southeast_asia": "Artemisinin resistance (Pfkrelch mutations) — urgent — treatment of resistant falciparum",
    "sub_saharan_africa": "Pediatric dosing, pregnancy, severe malaria, transmission blocking"
  }
}

# bash or zsh: see the payment challenge. Nothing is charged.
curl -sS -g -i 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials?condition=Disease+%E2%80%94+e.g.+%22Malaria%22+%7C+%22Tuberculosis%22+%7C+%22Dengue%22+%7C+%22Sickle+Cell+Disease%22+%7C+%22Chagas+Disease%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&region=global+%7C+africa+%7C+asia+%7C+europe+%7C+latin-america+%7C+middle-east+%7C+north-america+%28default%3A+global%29'

# x402 v2 sends the challenge base64-encoded in the PAYMENT-REQUIRED header (v1 sends it in the body).
# To read the header:
curl -sS -g -o /dev/null -D - 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials?condition=Disease+%E2%80%94+e.g.+%22Malaria%22+%7C+%22Tuberculosis%22+%7C+%22Dengue%22+%7C+%22Sickle+Cell+Disease%22+%7C+%22Chagas+Disease%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&region=global+%7C+africa+%7C+asia+%7C+europe+%7C+latin-america+%7C+middle-east+%7C+north-america+%28default%3A+global%29' \
  | grep -i '^payment-required:' | cut -d' ' -f2 | tr -d '\r' | base64 --decode

// npm i @x402/fetch @x402/evm viem
import { wrapFetchWithPayment, x402Client } from "@x402/fetch";
import { registerExactEvmScheme } from "@x402/evm/exact/client";
import { privateKeyToAccount } from "viem/accounts";

// Pays at most $0.15 per call.
const client = new x402Client().setSpendControls({ maxAmountPerPayment: "$0.15" });
registerExactEvmScheme(client, { signer: privateKeyToAccount(process.env.EVM_PRIVATE_KEY) });
const pay = wrapFetchWithPayment(fetch, client);

// Not sure it's safe to pay? ToolVet checks it first for $0.005. Pay for that from a separate
// client: this one is capped at $0.15 per payment. GET https://toolvet.app/api/v1/check?url=https%3A%2F%2Fclinicalintelpulse.theaslangroupllc.com%2Fapi%2Fclinical%2Fglobal-trials
const res = await pay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials?condition=Disease+%E2%80%94+e.g.+%22Malaria%22+%7C+%22Tuberculosis%22+%7C+%22Dengue%22+%7C+%22Sickle+Cell+Disease%22+%7C+%22Chagas+Disease%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&region=global+%7C+africa+%7C+asia+%7C+europe+%7C+latin-america+%7C+middle-east+%7C+north-america+%28default%3A+global%29");
console.log(res.status, await res.text());

# pip install "x402[requests,evm]"
import os
from eth_account import Account
from x402 import x402ClientSync
from x402.http.clients import x402_requests
from x402.mechanisms.evm import EthAccountSigner
from x402.mechanisms.evm.exact.register import register_exact_evm_client

# Pays at most $0.15 per call.
client = x402ClientSync().set_spend_controls({"max_amount_per_payment": "$0.15"})
register_exact_evm_client(client, EthAccountSigner(Account.from_key(os.environ["EVM_PRIVATE_KEY"])))

with x402_requests(client) as session:
    res = session.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials?condition=Disease+%E2%80%94+e.g.+%22Malaria%22+%7C+%22Tuberculosis%22+%7C+%22Dengue%22+%7C+%22Sickle+Cell+Disease%22+%7C+%22Chagas+Disease%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&region=global+%7C+africa+%7C+asia+%7C+europe+%7C+latin-america+%7C+middle-east+%7C+north-america+%28default%3A+global%29")
    print(res.status_code, res.text)